Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Dixon, Barry ^a   Schultz, Marcus J ^b   Smith, Roger ^a   Fink, James B ^c   Santamaria, John D ^a   Campbell, Duncan J ^d,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c GEORGIA STATE UNIVERSITY   (United States)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FIBRIN DEPOSITION; HUMAN; LUNG FUNCTION; LUNG INJURY; LUNG LAVAGE; MALE; NEBULIZER; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; METHODOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATION, ARTIFICIAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957663762     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9286     Document Type: Article

References (46)

1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005, 353:1685-1693. 10.1056/NEJMoa050333, 16236739.
2. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, Rana R, St Sauver JL, Lymp JF, Afessa B, Hubmayr RD. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004, 32:1817-1824. 10.1097/01.CCM.0000133019.52531.30, 15343007.
3. Parker JC, Hernandez LA, Peevy KJ. Mechanisms of ventilator-induced lung injury. Crit Care Med 1993, 21:131-143. 10.1097/00003246-199301000-00024, 8420720.
4. Kollef M, Pittet D, Sanchez Garcia M, Chastre J, Fagon JY, Bonten M, Hyzy R, Fleming TR, Fuchs H, Bellm L, Mercat A, Manez R, Martinez A, Eggimann P, Daguerre M, Luyt CE. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006, 173:91-97. 10.1164/rccm.200504-656OC, 16192451.
5. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004, 59:130-135. 10.1136/thorax.2003.013888, 1746934, 14760153.
6. Determann RM, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F, Hofstra JJ, de Graaff MJ, Korevaar JC, Schultz MJ. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. Crit Care 2010, 14:R1. 10.1186/cc8230, 2875503, 20055989.
7. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301-1308. 10.1056/NEJM200005043421801, 10793162.
8. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002, 346:1281-1286. 10.1056/NEJMoa012835, 11973365.
9. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003, 31:S213-220. 10.1097/01.CCM.0000057846.21303.AB, 12682443.
10. Yoshikawa T, Tanaka KR, Guze LB. Infection and disseminated intravascular coagulation. Medicine 1971, 50:237-258. 10.1097/00005792-197107000-00001, 4947125.
11. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976, 61:585-589. 10.1016/0002-9343(76)90135-2, 984062.
12. Tomashefski JF, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983, 112:112-126. 1916312, 6859225.
13. Dixon B, Opeskin K, Stamaratis G, Nixon I, Yi M, Newcomb AE, Rosalion A, Zhang Y, Santamaria JD, Campbell DJ. Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery. Thromb Res 2010,
14. Carraway MS, Welty-Wolf KE, Miller DL, Ortel TL, Idell S, Ghio AJ, Petersen LC, Piantadosi CA. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003, 167:1200-1209. 10.1164/rccm.200204-287OC, 12714343.
15. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988, 26:227-235.
16. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002, 18:236-241. 10.1097/00024382-200209000-00006, 12353924.
17. Cox CS, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993, 176:339-349.
18. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliott KT. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998, 9:274-281. 10.1097/00024382-199804000-00007, 9565256.
19. Weber JR, Angstwurm K, Rosenkranz T, Lindauer U, Freyer D, Burger W, Busch C, Einhaupl KM, Dirnagl U. Heparin inhibits leukocyte rolling in pial vessels and attenuates inflammatory changes in a rat model of experimental bacterial meningitis. J Cereb Blood Flow Metab 1997, 17:1221-1229. 10.1097/00004647-199711000-00011, 9390654.
20. Thomas R, Brooks T. Common oligosaccharide moieties inhibit the adherence of typical and atypical respiratory pathogens. J Med Microbiol 2004, 53:833-840. 10.1099/jmm.0.45643-0, 15314189.
21. Idanpaan-Heikkila I, Simon PM, Zopf D, Vullo T, Cahill P, Sokol K, Tuomanen E. Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia. J Infect Dis 1997, 176:704-712. 10.1086/514094, 9291319.
22. Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, Speert DP, Prince A. The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection. J Infect Dis 1999, 179:1449-1458. 10.1086/314755, 10228067.
23. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care 2004, 32:619-629.
24. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
25. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247. 10.1001/jama.290.2.238, 12851279.
26. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
27. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483-490. 10.1164/rccm.200612-1803OC, 17556722.
28. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulised heparin reduces pulmonary coagulation activation in acute lung injury. Crit Care 2010, 14:445.
29. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008, 12:R64. 10.1186/cc6894, 2481447, 18460218.
30. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, Schultz MJ. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 2009, 13:R145. 10.1186/cc8040, 2784363, 19740417.
31. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, van der Poll T, Levi M, Schultz MJ. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010, 23:105-111. 10.1089/jamp.2009.0779, 20073557.
32. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
33. Millo JL, Schultz MJ, Williams C, Weverling GJ, Ringrose T, Mackinlay CI, van der Poll T, Garrard CS. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 2004, 30:68-74. 10.1007/s00134-003-2060-0, 14634726.
34. Determann RM, Wolthuis EK, Choi G, Bresser P, Bernard A, Lutter R, Schultz MJ. Lung epithelial injury markers are not influenced by use of lower tidal volumes during elective surgery in patients without preexisting lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 294:L344-350. 10.1152/ajplung.00268.2007, 18083770.
35. Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. Intensive Care Med 2008, 34:1216-1223. 10.1007/s00134-008-1042-7, 18301879.
36. Good RTL. Studies on the generalized Shwartzman reaction IV. prevention of the local and generalized Shwartzman reaction by heparin. J Exp Med 1953, 97:871-888. 10.1084/jem.97.6.871, 2136309, 13069642.
37. Margaretten W, McKay D, Phillips LL. The effect of heparin on endotoxin shock in the rat. Am J Pathol 1967, 51:61-68. 1965334, 19971041.
38. Coalson JJ, Benjamin B, Archer LT, Beller B, Gilliam CL, Taylor FB, Hinshaw LB. Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock 1978, 5:423-437.
39. Abubakar K, Schmidt B, Monkman S, Webber C, de SD, Roberts R. Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Am J Respir Crit Care Med 1998, 158:1620-1625.
40. Cooper JR, Abrams J, Frazier OH, Radovancevic R, Radovancevic B, Bracey AW, Kindo MJ, Gregoric ID. Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg 2006, 131:963-968. 10.1016/j.jtcvs.2006.01.005, 16678576.
41. Jantsch H. Incidence and prognostic significance of pulmonary artery thromboses in patients with acute respiratory failure. Wien Klin Wochenschr Suppl 1989, 179:3-15.
42. Bertuglia S, Colantuoni A. Protective effects of leukopenia and tissue plasminogen activator in microvascular ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2000, 278:H755-761.
43. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99 m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999, 160:1653-1658.
44. Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 2002, 19:606-610. 10.1183/09031936.02.00105202, 11998987.
45. Perkins GD, Chatterjie S, McAuley DF, Gao F, Thickett DR. Role of nonbronchoscopic lavage for investigating alveolar inflammation and permeability in acute respiratory distress syndrome. Crit Care Med 2006, 34:57-64. 10.1097/01.CCM.0000190197.69945.C5, 16374157.
46. Determann RM, Royakkers AA, Haitsma JJ, Zhang H, Slutsky AS, Ranieri VM, Schultz MJ. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 2010, 10:6. 10.1186/1471-2466-10-6, 2841652, 20158912.